Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2010 1
2011 4
2012 3
2013 4
2014 1
2015 3
2016 4
2017 6
2018 4
2019 1
2020 8
2021 6
2022 5
2023 3
2024 2
2025 6
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.
Nishio S, Nishikawa T, Mori M, Kamiura S, Sumi T, Yunokawa M, Imai Y, Kondo E, Takehara K, Takano H, Kudaka W, Kado N, Yamagami W, Kato H, Nishino K, Usami T, Hamanishi J, Nii M, Takaya I, Okamoto A. Nishio S, et al. Among authors: kudaka w. J Gynecol Oncol. 2025 Jul;36(4):e118. doi: 10.3802/jgo.2025.36.e118. J Gynecol Oncol. 2025. PMID: 40590327 Free PMC article. Clinical Trial.
Prognostic factors of lenvatinib plus pembrolizumab therapy for advanced or recurrent endometrial cancer: analysis of a multicenter cohort study in Japan.
Nagase Y, Nakagawa S, Kobayashi M, Kurahashi H, Ogimoto H, Tanaka A, Tsujie T, Shiomi M, Otake A, Masuhara K, Yoshikawa K, Yotsumoto F, Kurita T, Yoshino K, Yoshioka E, Egawa-Takata T, Kudaka W, Sekine M, Unno H, Takemura M, Aso S, Kai K, Kobayashi E, Yokoi T, Akada M, Kakubari R, Hisa T, Matsuzaki S, Ueda Y. Nagase Y, et al. Among authors: kudaka w. Int J Clin Oncol. 2025 Nov;30(11):2342-2351. doi: 10.1007/s10147-025-02842-x. Epub 2025 Sep 6. Int J Clin Oncol. 2025. PMID: 40914783 Free PMC article.
Efficacy of Rikkunshito on Chemotherapy-Induced Nausea and Vomiting in Patients With Uterine Corpus or Cervical Cancer Treated With Cisplatin-Based Regimen-Placebo-controlled, Double-Blind, Randomized Confirmatory Study (JORTC-KMP03).
Konno Y, Ohnishi S, Minobe S, Nomura E, Nagasawa T, Fujimoto E, Ohara T, Nishio S, Kato H, Yokoyama Y, Miyagi E, Tokunaga H, Nishino K, Kikuchi A, Yoshida Y, Iwata T, Noguchi D, Kudaka W, Oyamada S, Ariyoshi K, Kihara K, Watari H. Konno Y, et al. Among authors: kudaka w. Integr Cancer Ther. 2025 Jan-Dec;24:15347354251329346. doi: 10.1177/15347354251329346. Epub 2025 Mar 29. Integr Cancer Ther. 2025. PMID: 40156342 Free PMC article. Clinical Trial.
Declining Prevalence of Human Papillomavirus Co-Infections Among Young Japanese Women With Cervical Cancer and Its Precursors.
Yoshiizumi E, Onuki M, Kukimoto I, Takahashi F, Matsui T, Hamasaki K, Kanao H, Nio A, Yahata H, Goda M, Yokoyama T, Hisa T, Tasaki K, Tenjimbayashi Y, Saji H, Kudaka W, Takei Y, Shigeta S, Motohara T, Matsumiya H, Nakamura K, Yoshida H, Ishikawa M, Hamanishi J, Nakai H, Mori-Uchino M, Hirashima Y, Sekizawa A, Yoshikawa H, Yaegashi N, Matsumoto K; MINT Study Group. Yoshiizumi E, et al. Among authors: kudaka w. J Med Virol. 2024 Dec;96(12):e70096. doi: 10.1002/jmv.70096. J Med Virol. 2024. PMID: 39639793
Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women.
Onuki M, Yamamoto K, Yahata H, Kanao H, Yokota H, Kato H, Shimamoto K, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Matsumura N, Yoshida H, Motohara T, Watari H, Nakamura K, Ueda A, Tasaka N, Ishikawa M, Hirashima Y, Kudaka W, Taguchi A, Iwata T, Takahashi F, Kukimoto I, Yoshikawa H, Yaegashi N, Matsumoto K; MINT Study Group. Onuki M, et al. Among authors: kudaka w. Cancer Sci. 2022 Apr;113(4):1428-1434. doi: 10.1111/cas.15270. Epub 2022 Feb 2. Cancer Sci. 2022. PMID: 35043515 Free PMC article.
A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.
Ishikawa M, Shibata T, Iwata T, Nishio S, Takada T, Suzuki S, Horie K, Kudaka W, Kagabu M, Tanikawa M, Kitagawa R, Takekuma M, Kobayashi H, Yaegashi N; Japan Clinical Oncology Group. Ishikawa M, et al. Among authors: kudaka w. Gynecol Oncol. 2021 Aug;162(2):292-298. doi: 10.1016/j.ygyno.2021.05.007. Epub 2021 May 18. Gynecol Oncol. 2021. PMID: 34016453 Clinical Trial.
54 results